# A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

> **NCT06280391** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 312 (actual)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** Itepekimab (SAR440340)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06280391
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-20
- **Primary completion:** 2025-09-16
- **Final completion:** 2026-02-02
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06280391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06280391, "A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06280391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*